title: Reply to V. Amoroso et al.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA lawrence_shulman@dfci.harvard.edu.
authors.forename: Lawrence N
authors.initials: LN
authors.lastname: Shulman
authors.affiliation: MD Anderson Cancer Center, Houston, TX.
authors.forename: Donald A
authors.initials: DA
authors.lastname: Berry
authors.affiliation: Duke University, Durham, NC.
authors.forename: Constance T
authors.initials: CT
authors.lastname: Cirrincione
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Clifford A
authors.initials: CA
authors.lastname: Hudis
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Eric P
authors.initials: EP
authors.lastname: Winer
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use*
chemical_list: D017239:Paclitaxel